Uterine Relaxants

Uterine relaxants, clinically referred to as tocolytics, are pharmacological agents used to inhibit uterine contractions and delay preterm labor.

The term "tocolysis" is derived from the Greek words tokos (childbirth) and lysis (loosening/dissolving).

Clinical Goals of Using Tocolytics

The objective of tocolytic therapy is rarely to prevent preterm birth indefinitely. Instead, the focus is on short-term prolongation of pregnancy (around 48 hours to 7 days) to allow for critical interventions that improve neonatal outcomes.

1. The "48-Hour Window" for Corticosteroids: The most significant goal is to delay delivery long enough to administer a full course of antenatal corticosteroids (e.g., Betamethasone or Dexamethasone). These steroids require approximately 48 hours to achieve maximum effect in stimulating fetal surfactant production, which significantly reduces the risk of Respiratory Distress Syndrome (RDS), intraventricular hemorrhage, and necrotizing enterocolitis in the neonate.
2. In Utero Transport: Delaying delivery provides time to safely transfer the pregnant person to a tertiary care facility with a Neonatal Intensive Care Unit (NICU) equipped to handle highly premature infants.
3. Magnesium Sulfate for Neuroprotection: For pregnancies less than 32 weeks gestation, tocolysis allows time to administer Magnesium Sulfate for fetal neuroprotection, which reduces the risk and severity of cerebral palsy.

Classification and Mechanisms of Action

Tocolytic agents are categorized by their pharmacological class. Each works through a different way to reduce the availability of intracellular calcium or decrease the sensitivity of uterine myofibrils to calcium, thereby inhibiting contractions.

Class	Primary Medication	Mechanism of Action
Beta-Adrenergic Agonists	Terbutaline (Brethine)	Stimulates β2-receptors in uterine smooth muscle. This increases intracellular cyclic adenosine monophosphate (cAMP), which leads to muscle relaxation.
Calcium Channel Blockers (CCBs)	Nifedipine (Procardia)	Inhibits the influx of extracellular calcium ions into the uterine smooth muscle cells (myometrium). Less calcium means the muscles cannot contract effectively.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)	Indomethacin (Indocin)	Blocks the enzyme cyclooxygenase (COX), which inhibits the synthesis of prostaglandins. Prostaglandins are potent stimulators of uterine contractions and cervical ripening.
Magnesium Sulfate	Magnesium Sulfate	Acts as a calcium antagonist. It competes with calcium for entry into the cell and displaces calcium from the sarcoplasmic reticulum, effectively "quieting" the electrical activity of the muscle.

Terbutaline (Brethine)

1. Classification

• Therapeutic Class: Tocolytic (Uterine Relaxant).
• Pharmacologic Class: Beta₂-Adrenergic Agonist (Sympathomimetic).
• Legal Classification: Prescription Only (Schedule VI in various jurisdictions).

2. Available Forms and Precise Dosages

Subcutaneous (SC) Injection:

• Dosage: 0.25 mg administered every 20 minutes to 3 hours.
• Note: Primarily used for short-term "rescue" tocolysis or to delay delivery for maternal transport/steroid administration.

Intravenous (IV) Infusion:

• Dosage: Start at 2.5–5 mcg/min; increase by 2.5 mcg/min every 20 minutes.
• Maximum Dose: Generally capped at 25 mcg/min depending on maternal heart rate and uterine response.

Oral (PO):

• Note: No longer recommended for long-term maintenance tocolysis due to FDA Black Box warnings regarding cardiac risks.

3. Indications and Contraindications

Indications

• Preterm Labor: Management of preterm labor in pregnancies between 20 and 34 weeks gestation.
• Uterine Hyperstimulation: Treatment of uterine tachysystole (with or without fetal heart rate changes).

Contraindications

• Maternal Cardiac Disease: Pre-existing structural heart disease or arrhythmias.
• Uncontrolled Hyperthyroidism: Risk of thyroid storm or severe tachycardia.
• Poorly Controlled Diabetes: Risk of severe hyperglycemia and ketoacidosis.
• Gestational Age >34 Weeks: Risk-benefit ratio shifts toward delivery.
• Cervical Dilation >4 cm: Advanced labor where tocolysis is unlikely to be effective.

4. Side Effects and Adverse Effects

Maternal Effects

• Tachycardia: Significant increase in heart rate due to cross-stimulation of Beta₁ receptors.
• Palpitations and Tremors: Common peripheral nervous system side effects.
• Hypokalemia: Intracellular shifting of potassium; requires monitoring of serum levels.
• Hyperglycemia: Stimulation of glycogenolysis in the liver.
• Pulmonary Edema: A severe adverse effect, often associated with fluid overload or concurrent corticosteroid use.
• Hypotension: Resulting from peripheral vasodilation.

Fetal/Neonatal Effects

• Fetal Tachycardia: Direct result of the drug crossing the placenta.
• Neonatal Hypoglycemia: Reactive hyperinsulinemia in the neonate following maternal hyperglycemia.

5. Drug Interactions

• Beta-Blockers: Antagonize the effects of Terbutaline, rendering it ineffective.
• Corticosteroids: Significantly increases the risk of maternal pulmonary edema.
• Diuretics: Can exacerbate Terbutaline-induced hypokalemia.

6. Nursing Care and Administration

Assessments

• Vital Signs: Monitor maternal pulse and blood pressure every 15 minutes during IV titration; hold dose if maternal HR >120 bpm.
• Fetal Heart Rate (FHR): Continuous electronic monitoring to detect tachycardia or distress.
• Lung Sounds: Auscultate every 4 hours to check for crackles (early sign of pulmonary edema).
• I/O Monitoring: Strict fluid intake/output tracking; limit fluid intake to 1,500–2,500 mL/24 hours to prevent fluid overload.

Administration Guidelines

• IV Setup: Administer via a secondary infusion pump for precise titration.
• Patient Positioning: Maintain the patient in a lateral recumbent position to maximize placental perfusion and minimize hypotension.
• Laboratory Review: Monitor blood glucose and potassium levels frequently during prolonged administration.
• Patient Education: Instruct the patient to report chest pain, shortness of breath, or "racing" heart immediately.

Salbutamol (Albuterol)

1. Classification

• Therapeutic Class: Tocolytic (Uterine Relaxant); Bronchodilator.
• Pharmacologic Class: Short-Acting Beta₂-Adrenergic Agonist (SABA).
• Legal Classification: Prescription Only (Schedule VI).

2. Available Forms and Precise Dosages

Intravenous (IV) Infusion:

• Standard Concentration: Often 5 mg diluted in 500 mL of 5% Glucose or 0.9% Normal Saline.
• Titration: Initial rate of 10 mcg/min (1.2 mL/min of the standard solution).
• Increments: Increase by 10 mcg/min every 10–20 minutes until uterine contractions cease or side effects become intolerable.
• Maximum Dose: capped at 45–60 mcg/min.

Subcutaneous (SC)/Intramuscular (IM) Injection:

• Dosage: 100–500 mcg every 4 hours, primarily used for acute stabilization or transport.

Oral (PO):

• Note: Similar to Terbutaline, oral use for maintenance tocolysis is generally avoided due to poor efficacy and high maternal cardiac risk.

3. Indications and Contraindications

Indications

• Preterm Labor (Uncomplicated): Short-term (up to 48 hours) management to allow for corticosteroid administration or maternal transfer.
• External Cephalic Version: To relax the uterus during attempts to turn a breech fetus.
• Uterine Hypertonus: Emergency management of tetanic contractions during labor.

Contraindications

• Cardiac Disease: Pre-existing ischemic heart disease, severe hypertension, or hypertrophic cardiomyopathy.
• Antepartum Hemorrhage: Conditions such as placenta previa or abruption where delay of delivery may endanger the mother/fetus.
• Eclampsia/Severe Pre-eclampsia: The cardiovascular strain of Salbutamol can worsen maternal status.
• Intrauterine Infection: Tocolysis is contraindicated in the presence of chorioamnionitis.
• Fetal Compromise: Evidence of fetal distress or intrauterine growth restriction (IUGR).

4. Side Effects and Adverse Effects

Maternal Effects

• Reflex Tachycardia: Compulsory monitoring required; hold dose if HR exceeds 130–140 bpm.
• Hypotension: Due to Beta₂-mediated vasodilation of peripheral blood vessels.
• Tremors and Anxiety: Stimulation of skeletal muscle receptors leads to fine tremors and nervousness.
• Hypokalemia: Shifts potassium into cells, potentially causing arrhythmias.
• Metabolic Acidosis/Hyperglycemia: Enhanced glycogenolysis; particularly dangerous in diabetic patients.
• Chest Pain: May indicate myocardial ischemia in susceptible patients.

Fetal/Neonatal Effects

• Fetal Tachycardia: Crosses the placenta directly; fetal HR often mirrors maternal HR increases.
• Hyperinsulinism: Fetal response to maternal hyperglycemia, leading to neonatal hypoglycemia post-delivery.

5. Drug Interactions

• Beta-Adrenergic Blockers: Negate the tocolytic effect (e.g., Propranolol).
• Corticosteroids (Dexamethasone/Betamethasone): Synergy in causing pulmonary edema and severe hyperglycemia.
• Non-Potassium Sparing Diuretics: Potentiates the risk of life-threatening hypokalemia.

6. Nursing Care and Administration Protocols

Assessments

• Maternal Heart Rate: Monitor continuously or every 10 minutes during titration; withhold if pulse >140 bpm.
• Fluid Balance: Maintain strict intake/output records; fluid restriction is often implemented (e.g., <2,000 mL/day).
• Respiratory Status: Observe for dyspnea, chest tightness, or productive cough (indicators of pulmonary edema).
• Blood Chemistry: Frequent monitoring of blood glucose and serum potassium.

Administration Guidelines

• IV Delivery: Use an infusion pump and a dedicated IV line; never bolus Salbutamol for tocolysis.
• Dilution: Ensure compatibility with carrier fluids (avoid highly concentrated dextrose if the patient is diabetic).
• Post-Treatment Monitoring: Continue monitoring for at least 12 hours after the infusion stops for rebound effects or pulmonary complications.
• Patient Education: Reassure the patient that tremors and palpitations are expected side effects but to report chest pain immediately.

Nifedipine (Calcium Channel Blocker)

Legal and Medical Classifications

• Pharmacological Class: Calcium Channel Blocker (Dihydropyridine derivative). It inhibits the influx of calcium ions through "slow channels" into vascular smooth muscle and myocardium.
• Therapeutic Class: Tocolytic / Antihypertensive. In obstetrics, it is used off-label to delay preterm labor by relaxing uterine smooth muscle.
• Pregnancy Category: Category C. Human studies are limited, but it is widely used as a first-line tocolytic due to a more favorable side-effect profile compared to beta-agonists.

Available Forms and Precise Dosages

• Oral Immediate-Release (IR) Capsules: Preferred for rapid onset during the initial "loading" phase of tocolysis.
• Oral Extended-Release (ER/XL) Tablets: Used for maintenance therapy to provide stable plasma concentrations.
• Loading Dose: 10–20 mg orally every 20 minutes for up to 3 doses. This rapid titration aims to achieve therapeutic levels quickly to stop contractions.
• Maintenance Dose: 10–20 mg orally every 4–8 hours. The total daily dose should not exceed 120 mg to minimize systemic cardiovascular risks.

Indications and Contraindications

• Indications: Management of preterm labor (24–34 weeks gestation). It is used to delay delivery for 48 hours to allow for corticosteroid administration (fetal lung maturation) and GBS prophylaxis.
• Contraindications (Maternal): Hypersensitivity to nifedipine or other dihydropyridines.
• Contraindications (Cardiovascular): Severe hypotension (BP < 90/60 mmHg) or preload-dependent cardiac states (e.g., aortic stenosis), as vasodilation may cause critical drops in cardiac output.
• Contraindications (Obstetric): Intrauterine infection (chorioamnionitis), fetal distress, or premature rupture of membranes (PROM) with signs of infection, where delaying delivery is unsafe.

Side Effects and Adverse Effects

• Maternal Hypotension: Peripheral vasodilation reduces systemic vascular resistance, which can lead to lightheadedness or syncope.
• Reflex Tachycardia: A compensatory mechanism where the heart rate increases in response to a drop in blood pressure caused by vasodilation.
• Facial Flushing and Headache: Resulting from the dilation of cutaneous and cerebral blood vessels.
• Peripheral Edema: Increased capillary hydrostatic pressure caused by precapillary vasodilation leads to fluid extravasation into tissues.
• Fetal Effects: Generally considered safe with minimal impact on fetal heart rate, though severe maternal hypotension can theoretically lead to decreased uteroplacental perfusion and fetal hypoxia.

Drug Interactions

• Magnesium Sulfate: Concurrent use is controversial and requires extreme caution. Both are calcium antagonists and can synergistically cause profound hypotension and neuromuscular blockade.
• Beta-Blockers: May increase the risk of congestive heart failure or severe hypotension by suppressing compensatory tachycardia.
• Grapefruit Juice: Inhibits CYP3A4 metabolism of nifedipine, significantly increasing plasma concentrations and the risk of toxicity.
• Antihypertensives: Enhanced hypotensive effect when combined with other vasodilators or diuretics.

Nursing Care and Administration

• Blood Pressure Monitoring: Assess BP and pulse immediately before each dose and every 15–30 minutes during the loading phase. Hold medication if BP is < 90/60 or if significant tachycardia is present.
• Administration Route: Capsules should be swallowed whole. Sublingual administration is strictly contraindicated in obstetrics due to the risk of unpredictable, precipitous drops in blood pressure.
• Patient Positioning: Maintain the patient in a left lateral recumbent position to maximize uteroplacental perfusion and minimize orthostatic hypotension.
• Fluid Balance: Monitor Intake and Output (I&O) and assess for signs of pulmonary edema, especially if the patient is receiving concurrent IV fluids or steroids.
• Fetal Assessment: Continuous electronic fetal monitoring (EFM) is required during the loading phase to ensure fetal well-being remains stable as maternal hemodynamics shift.
• Patient Education: Instruct the patient to rise slowly from a sitting or lying position to prevent falls from orthostatic hypotension.

Indomethacin (NSAID)

Classification

• Therapeutic Class: Antipyretic, analgesic, nonsteroidal anti-inflammatory drug (NSAID).
• Pharmacologic Class: Nonselective cyclooxygenase (COX) inhibitor.
• Pregnancy Category: Category B (first and second trimester); Category D (third trimester/after 30 weeks gestation).

Available Forms and Dosage

• Oral (Capsules): 25 mg and 50 mg.
• Rectal (Suppositories): 50 mg.
• Loading Dose: 50 mg to 100 mg administered orally or rectally.
• Maintenance Dose: 25 mg to 50 mg every 6 hours for a maximum of 48 hours.
• Dosage Limitation: Treatment is strictly limited to 48 hours to prevent premature closure of the fetal ductus arteriosus.
• Gestational Age Limit: Typically not administered after 32 weeks gestation due to increased fetal risks.

Indications

• Preterm Labor Suppression: Used as a first-line or second-line tocolytic, particularly for early preterm labor (less than 30–32 weeks).
• Polyhydramnios Management: Reduces fetal urine production to lower amniotic fluid volume.

Contraindications

• Maternal Asthma: Risk of bronchospasm (aspirin-sensitive asthma triad).
• Active Peptic Ulcer Disease: Risk of gastrointestinal hemorrhage or perforation.
• Coagulation Disorders: Interference with platelet aggregation increases bleeding risk.
• Renal Impairment: Reduces renal blood flow and glomerular filtration rate.
• Gestational Age >32 Weeks: High risk for fetal ductus arteriosus constriction.
• Suspected Fetal Heart Defect: Especially ductal-dependent lesions.

Side Effects and Adverse Effects

Maternal

• Gastrointestinal Distress: Nausea, vomiting, and dyspepsia due to inhibition of protective prostaglandins in the gastric mucosa.
• Platelet Dysfunction: Increased bleeding time because COX-1 inhibition prevents thromboxane A₂ production.
• Peripheral Edema: Prostaglandin inhibition in the kidneys leads to sodium and water retention.

Fetal

• Premature Closure of Ductus Arteriosus: Inhibition of PGE₂ (which keeps the ductus patent) causes constriction, potentially leading to pulmonary hypertension.
• Oligohydramnios: Reduced fetal renal blood flow leads to decreased urine output, lowering amniotic fluid volume.
• Necrotizing Enterocolitis (NEC): Possible reduction in fetal mesenteric blood flow.
• Intraventricular Hemorrhage (IVH): Related to alterations in fetal cerebral blood flow and platelet function.

Drug Interactions

• Anticoagulants/Antiplatelets: Potentiates bleeding risks.
• ACE Inhibitors/Diuretics: Increases risk of renal failure due to combined effects on renal hemodynamics.
• Lithium: May increase lithium levels to toxic ranges by decreasing renal clearance.

Nursing Care and Assessments

Administration

• Administer with Food/Milk: Reduces gastric irritation and risk of ulceration.
• Rectal Administration: Consider if the patient is experiencing significant nausea or vomiting.
• Adherence to 48-Hour Limit: Meticulous tracking of start time to prevent prolonged fetal exposure.

Maternal Assessments

• Gastrointestinal Screening: Monitor for epigastric pain or occult blood in stool.
• Respiratory Assessment: Check for wheezing or shortness of breath, especially in patients with a history of allergies.
• Renal Function Monitoring: Track Intake and Output (I&O) and serum creatinine if therapy is repeated.

Fetal Assessments

• Ultrasound Evaluation: Assessment of amniotic fluid index (AFI) before and during therapy to detect oligohydramnios.
• Fetal Echocardiogram: Indicated if therapy exceeds 48 hours to monitor for ductal constriction (evidenced by increased flow velocity).
• Continuous Fetal Monitoring: Assessing for non-reassuring heart rate patterns related to decreased placental or fetal perfusion.

Magnesium Sulfate (MgSO₄)

Legal and Medical Classifications

• Legal Classification: Class B Controlled Drug (Prescription Only Medication).
• Medical Classification: Anticonvulsant, Tocolytic, Electrolyte Replenisher, and Osmotic Laxative.

Available Forms and Strengths

• Form: Sterile aqueous solution for intravenous (IV) or intramuscular (IM) injection.
• Common Strength: 50% solution (5 g/10 ml), 20% solution (2 g/10 ml), or 10% solution (1 g/10 ml).

Indications

• Preeclampsia and Eclampsia: Used primarily to prevent and control seizures. It acts as a CNS depressant and blocks neuromuscular transmission.
• Fetal Neuroprotection: Administered in anticipated preterm birth (usually <32 weeks) to reduce the risk of cerebral palsy.
• Tocolysis: Utilized as a secondary agent to inhibit uterine contractions by competing with calcium at the cellular level, thereby decreasing myometrial contractility.
• Hypomagnesemia: Correction of magnesium deficiency.
• Severe Asthma: Bronchodilation via smooth muscle relaxation.

Dosage and Administration Protocols

Loading Dose (Total 14 g)

• Intravenous (IV) Component: 4 g of MgSO₄ administered slowly over 15–20 minutes.
  • Preparation: Draw 8 ml of 50% MgSO₄ (4 g) into a 20 ml syringe. Add 12 ml of water for injection to create a 20% solution (4 g in 20 ml).
• Intramuscular (IM) Component: 10 g administered immediately following the IV dose.
  • Preparation: Draw 10 ml of 50% MgSO₄ (undiluted 5 g) into each of two 20 ml syringes. Add 1 ml of 2% Lignocaine to each to minimize injection site pain.
  • Administration: Deep IM injection into each buttock (Z-track method recommended).

Maintenance Dose

• Dosage: 5 g of 50% MgSO₄ every 4 hours.
• Preparation: 10 ml of 50% MgSO₄ plus 1 ml of 2% Lignocaine.
• Duration: Continued for 24 hours after the last seizure or 24 hours post-delivery.
• Breakthrough Seizures: If a seizure occurs before the next scheduled dose, an additional 2 g may be given slowly IV.

Contraindications

• Myasthenia Gravis: Magnesium inhibits acetylcholine release at the neuromuscular junction, which can precipitate a fatal myasthenic crisis.
• Renal Impairment: Magnesium is excreted solely by the kidneys; impaired clearance leads to rapid toxic accumulation.
• Myocardial Damage/Heart Block: Magnesium affects cardiac conduction and can exacerbate existing heart blocks.
• Hypocalcemia: High magnesium levels further suppress calcium, risking tetany or cardiac arrest.

Side Effects and Adverse Effects

Maternal Effects

• Flushing and Diaphoresis: Result of peripheral vasodilation.
• Nausea and Vomiting: Gastric irritation and CNS effects.
• Muscle Weakness: Inhibition of neuromuscular transmission.
• Hypotension: Due to smooth muscle relaxation in the vascular walls.

Fetal/Neonatal Effects

• Neonatal Hypotonia: "Floppy baby" syndrome due to neuromuscular blockade crossing the placenta.
• Respiratory Depression: Reduced drive in the neonate if maternal levels are high.
• Reduced Fetal Heart Rate (FHR) Variability: CNS depressant effect on the fetus.

Toxicity (Hypermagnesemia)

• Loss of Deep Tendon Reflexes (DTRs): Occurs at 7–10 mEq/L; magnesium interferes with the release of acetylcholine at the motor endplate.
• Respiratory Depression: Occurs at >10–12 mEq/L; paralysis of respiratory muscles.
• Cardiac Arrest: Occurs at >25 mEq/L; profound electrical conduction interference.

Drug Interactions

• Calcium Channel Blockers (e.g., Nifedipine): Synergistic effect can lead to severe hypotension and neuromuscular blockade.
• Neuromuscular Blockers: Potentiates the effect of agents like vecuronium.
• Digitalis: Magnesium toxicity can be masked or cardiac arrhythmias exacerbated.

Nursing Care and Assessments

Pre-Administration Assessment

• Verify presence of Patellar Reflex (Knee Jerk): If absent, the drug must be withheld as this is the first sign of toxicity.
• Respiratory Rate (RR): Must be >12–16 breaths/min.
• Urinary Output: Must be >30 ml/hr (or 100 ml/4 hours) to ensure adequate drug excretion.

Monitoring during Therapy

• Continuous Fetal Monitoring: Assessing for loss of variability or bradycardia.
• Strict Intake/Output: Use of a Foley catheter to monitor renal clearance accurately.
• Bed Rest/Safety: Side rails up and seizure precautions due to sedation and muscle weakness.

Management of Toxicity

• Antagonist: Calcium Gluconate (10% solution).
• Dose: 1 g (10 ml) given slowly IV over 3 minutes.
• Mechanism: Calcium directly antagonizes the neuromuscular and cardiac effects of magnesium.